Feb 17, 2026 07:02AM
Feb 17, 2026 07:00AM
Feb 5, 2026 07:43AM
Feb 5, 2026 07:00AM
Jan 21, 2026 07:00AM
Jan 21, 2026 07:00AM
Dec 8, 2025 07:02AM Ocular Therapeutix plans to accelerate AXPAXLI submission for wet AMD
Dec 8, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 4, 2025 07:12AM
Nov 4, 2025 07:05AM
Nov 4, 2025 07:02AM
Nov 4, 2025 07:00AM Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
Oct 28, 2025 07:00AM
Sep 30, 2025 06:21AM
Sep 30, 2025 06:21AM
Aug 12, 2025 07:01AM
Aug 12, 2025 07:00AM
Aug 5, 2025 11:11AM
Aug 5, 2025 11:07AM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)
Aug 5, 2025 07:13AM
Aug 5, 2025 07:00AM
Jul 29, 2025 07:00AM
May 5, 2025 07:04AM
May 5, 2025 07:00AM
Apr 28, 2025 07:00AM
Mar 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
Mar 3, 2025 07:10AM
Mar 3, 2025 07:00AM
Feb 24, 2025 07:00AM
Jan 14, 2025 07:03AM
Jan 14, 2025 07:00AM
Dec 2, 2024 07:30AM
Nov 15, 2024 06:51AM Ocular Therapeutix (OCUL) PT Raised to $15 at H.C. Wainwright
Nov 14, 2024 07:04AM
Nov 14, 2024 07:00AM
Nov 12, 2024 07:31AM
Nov 12, 2024 07:30AM
Nov 6, 2024 07:30AM
Oct 15, 2024 07:31AM
Oct 15, 2024 07:30AM Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
Aug 7, 2024 07:14AM
Aug 7, 2024 07:10AM
Aug 7, 2024 07:02AM
Aug 7, 2024 07:00AM
Jul 31, 2024 07:30AM
Jul 30, 2024 07:30AM
Jun 13, 2024 04:05PM Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
May 8, 2024 06:49AM

1,168,522 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All